ClinicalTrials.gg
CompletedNCT01192113Updated Nov 7, 2012

Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109)

A Phase 4 interventional study of Mecobalamin IV Injection and Mecobalamin IM injection in Peripheral Neuropathy, sponsored by Eisai Co., Ltd.. Completed at 24 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-11-07.

Sponsored by Eisai Co., Ltd. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,072
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Peripheral Nervous System Diseases with a site in China — 5 open to participants now, 5 under way, 1 of them phase 3. Peripheral Nervous System Diseases · China.

Enrollment
Largest of 14
1,072 · median 109
Started
2010
the only one that year
Phase 4
Only one
of the 18
Registered
1st of 18
by date
Lead sponsor
1 of 18
Eisai Co., Ltd.

Among the 18 studies in Peripheral Nervous System Diseases with a site in China, this one has the largest enrollment of the 14 interventional ones that give a count, is the only one that started in 2010, is the only one in phase 4, and was the 1st registered.

Peripheral Nervous System Diseases

476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.

Browse Peripheral Nervous System Diseases studies →

Open to participants now

5 of the 18 studies in Peripheral Nervous System Diseases with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Peripheral Nervous System Diseases with a site in China, or all of them as a file.
02

Study summary

This is an open-label, randomized, multi-center clinical trial to evaluate the safety and efficacy in peripheral neuropathies patients treated with Mecobalamin Injection

03

Conditions studied

  • Peripheral Neuropathy

Keywords

  • Mecobalamin
  • peripheral neuropathy
  • diabetic neuropathy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of diabetes induced peripheral neuropathy, other peripheral neuropathies (Idiopathic, nutritional and metabolic nature of entrapment neuropathy).
  2. Significant spontaneous pain and / or numbness and other symptoms of neuropathy. TSS (Total Symptom Score) >=7.5.
  3. Participation in clinical trials voluntarily and signed form

Exclusion criteria

Exclusion criteria:

  1. Pregnancy, preparation for pregnancy or breast-feeding women
  2. Peripheral neuropathy caused by drugs, poisoning, cancer or genetic
  3. (ALT), aspartate aminotransferase (AST): 2.0 times more than the ; Creatinine (Cr) 1.5 times above the upper limit of normal.
  4. Serious organ disease or other serious primary disease merger, the mentally ill, poorly controlled hypertension (blood pressure more than 150/100 mmHg after using antihypertensive drugs)
  5. Diagnosis of patients with diabetic peripheral neuropathy, but has diabetes ketosis, ketoacidosis and severe infection within the past two weeks
  6. Bleeding or bleeding tendency in 2 months
  7. Have allergy
  8. Noncompliance or cannot meet those
  9. Participation in other clinical trials in the last 3 months
  10. Participant unsuitable to participate in this test as investigator considering
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,072 participants (actual)

Study arms

  • Experimental
    Group A: Diabetic Peripheral Neuropathy (IV)

    Drug: Mecobalamin IV Injection

  • Experimental
    Group B: Diabetic Peripheral Neuropathy (IM)

    Drug: Mecobalamin IM injection

  • Experimental
    Group C: Idiopathic Peripheral Neuropathy

    Drug: Mecobalamin IV or IM injection

  • Experimental
    Group D: Nutritional & Metabolic Peripheral Neuropathy

    Drug: Mecobalamin IV or IM injection

  • Experimental
    Group E: Compression Peripheral Neuropathy

    Drug: Mecobalamin IV or IM injection

Interventions

  • Mecobalamin injection 0.5 mg/ ml administered as an intravenous (IV) injection 3 times a week for four weeks

  • DrugMecobalamin IM injection

    Mecobalamin injection 0.5 mg/ ml administered as an intramuscular (IM) injection 3 times a week for four weeks

  • DrugMecobalamin IV or IM injection

    Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks

06

What researchers measure

Primary outcomes

  1. Value of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline

    The TSS of peripheral neuropathy is used to score the intensity \& frequency of four symptoms in participants' feet/legs including: pain, burning sensation, numbness, and hypoesthesia. Frequency is ranked as asymptomatic, occasionally (2-3 times/ week), often (1-2 times/ day), \& continuous (nearly all day). Intensity is evaluated by visual analogue scale (VAS) score: 0 (zero intensity)- 10 (max. intensity). Participants described intensity by marking the number corresponding to severity of symptom they felt in a 10 cm long straight line and investigators distinguished whether it was mild (score: 1-3), moderate (score: 4-6), or severe (score: 7-10). The total score of four symptoms was considered the TSS. Total scores ranged from 0-14.64 points, where 0 was lowest symptom score and 14.64 was most severe level of symptoms. Baseline (before treatment) scores were compared to scores after 4 weeks of treatment.

    Time frame: Baseline & End of Week 4

  2. Rate of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline

    TSS of peripheral neuropathy is used to score the intensity \& frequency of 4 symptoms in participants' feet/legs including: pain, burning sensation, numbness, hypoesthesia. Frequency is ranked as asymptomatic, occasionally (2-3 times/ week), often (1-2 times/ day), \& continuous (nearly all day). Intensity is evaluated by visual analogue scale (VAS) score: 0 (zero intensity)- 10 (max. intensity). Participants described intensity by marking the number corresponding to severity of symptom they felt in a 10 cm long straight line and investigators distinguished whether it was mild (score: 1-3), moderate (score: 4-6), or severe (score: 7-10). The total score of four symptoms was considered the TSS. Total scores ranged from 0-14.64 points, where 0 was lowest symptom score and 14.64 was most severe level of symptoms. Baseline scores were compared to TSS decreasing rate after 4 weeks of treatment. Rate of TSS change = (TSS difference value/TSS before treatment)×100%.

    Time frame: Baseline and End of Week 4

Secondary outcomes

  1. Value of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline

    The TSS of peripheral neuropathy is used to score the intensity \& frequency of four symptoms in participants' feet/legs including: pain, burning sensation, numbness, and hypoesthesia. Frequency is ranked as asymptomatic, occasionally (2-3 times/ week), often (1-2 times/ day), \& continuous (nearly all day). Intensity is evaluated by visual analogue scale (VAS) score: 0 (zero intensity)- 10 (max. intensity). Participants described intensity by marking the number corresponding to severity of symptom they felt in a 10 cm long straight line and investigators distinguished whether it was mild (score: 1-3), moderate (score: 4-6), or severe (score: 7-10). The total score of four symptoms was considered the TSS. Total scores ranged from 0-14.64 points, where 0 was lowest symptom score and 14.64 was most severe level of symptoms. Baseline (before treatment) scores were compared to scores after 2 weeks of treatment.

    Time frame: Baseline and End of Week 2

  2. Rate of the Peripheral Neuropathy Total Symptom Score (TSS) Compared to Baseline

    TSS of peripheral neuropathy is used to score the intensity/ frequency of 4 symptoms in participants' feet/legs including: pain, burning sensation, numbness, and hypoesthesia. Frequency is ranked as asymptomatic, occasionally (2-3 times/ week), often (1-2 times/ day), \& continuous (nearly all day). Intensity is evaluated by visual analogue scale (VAS) score: 0 (zero intensity)- 10 (max. intensity). Participants described intensity by marking the number corresponding to severity of symptom they felt in a 10 cm long straight line and investigators distinguished whether it was mild (score: 1-3), moderate (score: 4-6), or severe (score: 7-10). The total score of four symptoms was considered the TSS. Total scores ranged from 0-14.64 points, where 0 was lowest symptom score and 14.64 was most severe level of symptoms. Baseline scores were compared to TSS decreasing rate after 2 weeks of treatment. Rate of TSS change = (TSS difference value/TSS before treatment)×100%.

    Time frame: Baseline and End of Week 2

  3. Value of the Neural Injury Score of the Lower Limbs (NIS-LL) Compared to Baseline

    The Neural Injury Score of the Lower Limbs (NIS-LL) was scored based on the following examination items: muscle strength (including hip \& knee flexion/ extension \& remote foot dorsiflexion/ plantar flexion \[scored as normal, 25% weak, 50% weak, 75% weak, and paralysis\]), reflex (response at the quadriceps \& ankle \[normal score=0, decreased score=1, absent score=2\], and sensory (tested at the great toe; including touch pressure, pinprick ,vibration, and joint position \[normal score=0, decreased score=1, absent score=2\]). The Total NIS-LL score ranged from 0-8 points where a higher score means greater neural injury of the lower limbs. Baseline (before treatment) scores were compared to scores after 4 weeks of treatment.

    Time frame: Baseline and End of Week 4

  4. Rate of the Neural Injury Score of the Lower Limbs (NIS-LL) Compared to Baseline

    The Neural Injury Score of the Lower Limbs (NIS-LL) was scored based on the following examination items: muscle strength (including hip \& knee flexion/ extension \& remote foot dorsiflexion/ plantar flexion \[scored as normal, 25% weak, 50% weak, 75% weak, and paralysis\]), reflex (response at the quadriceps \& ankle \[normal score=0, decreased score=1, absent score=2\], and sensory (tested at the great toe; including touch pressure, pinprick ,vibration, and joint position \[normal score=0, decreased score=1, absent score=2\]). The Total NIS-LL score ranged from 0-8 points where a higher score means greater neural injury of the lower limbs. Baseline (before treatment) scores were compared to scores after 4 weeks of treatment. Rate of NIS-LL change = (NIS-LL difference value/NIS-LL before treatment)×100%.

    Time frame: Baseline and End of Week 4

07

Study locations

24 sites
  • The 1st Hospital of Anhui Medical University
    Hefei, Anhui, China
  • The General Hospital of the People's Liberation Army
    Beijing, Beijing, China
  • The institute of rehabilitation medicine
    Beijing, Beijing, China
  • Nanfang Hospital of Nanfang Medical Unversity
    Guangzhou, Guangdong, China
  • The 1st People Hospital of Guangzhou
    Guangzhou, Guangdong, China
  • the 1st Hospital affliated to Guangxi Medical University
    Nanning, Guangxi, China
  • The 3rd Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • the people Hospital
    Wuhan, Hubei, China
  • Tongji Hospital
    Wuhan, Hubei, China
  • Xiehe Hospital
    Wuhan, Hubei, China
  • the 1st Hospital of Nanjing
    Nanjing, Jiangsu, China
  • Zhong Xi Yi Jie He Hospital of Jiangsu
    Nanjing, Jiangsu, China
  • the 2nd Hospital of Suzhou University
    Suzhou, Jiangsu, China
  • Subei People Hospital
    Yangzhou, Jiangsu, China
  • The 1st People Hospital of Yangzhou
    Yangzhou, Jiangsu, China
  • the Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu, China
  • Changhai Hospital
    Shanghai, Shanghai, China
  • Ruijing Hospital
    Shanghai, Shanghai, China
  • the 10th People Hospital of Shanghai
    Shanghai, Shanghai, China
  • the 10th People Hospital
    Shanghai, Shanghai, China
  • The 1st Center Hospital of Tianjin
    Tianjin, Tianjin, China
  • The institute of rehabilitation medicine
    Beijing, China
  • Rui Jin Hospital
    Shanghai, China
  • Shenzhen Hospital of Beijing University
    Shenzhen, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2010
First posted
Aug 31, 2010
Start
Apr 2010
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Nov 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01192113
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Aug 31, 2010
Start date
Apr 2010
Primary completion
May 2011
Completion
May 2011
Last update
Nov 7, 2012

Study contacts

Jvming Lu
principal investigator · Chinese PLA General Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mecobalamin

Start the discussion